A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., based in Edmonton. Aurora has set up a special committee to review the unsolicited bid following an announcement by Curaleaf Holdings Inc. that it intends to purchase all of Aurora’s shares, creating a combined cannabis entity operating in 17 countries worldwide.
Curaleaf, headquartered in Stamford, Connecticut, and listed on the Toronto Stock Exchange, disclosed its bid publicly after unsuccessful private negotiations with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7 outlining the proposal, Aurora’s board declined to engage in discussions, prompting Curaleaf to approach Aurora shareholders directly.
Curaleaf proposes to pay $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each share. Aurora confirmed receipt of the letters from Curaleaf but disputed the claim that it refused to engage with the offer. The Canadian company stated that its lead independent director had ongoing correspondence with Curaleaf’s CEO as recently as July 24.
Aurora plans to convene a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests. The company emphasized that a deal is not guaranteed, and operations will continue as usual in the interim. While acknowledging Curaleaf’s interest, analysts caution that the current offer undervalues Aurora’s long-term potential, citing its market leadership in medical cannabis and strong international presence.
Curaleaf believes that merging with Aurora would leverage its global distribution network with Aurora’s medical cannabis franchise and manufacturing capabilities. The combined revenue of both companies exceeded $1.5 billion US over the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed takeover. Jordan, Curaleaf’s CEO, views the merger as a mutually beneficial opportunity for shareholders to access a diversified global platform and capitalize on U.S. regulatory trends.
